Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Apr;106(5):519-522.
doi: 10.1002/bjs.11168. Epub 2019 Mar 18.

Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma

B Schermers  1   2 , V Franke  1 , E A Rozeman  3 , B A van de Wiel  4 , A Bruining  5 , M W Wouters  1 , W J van Houdt  1 , B Ten Haken  2 , S H Muller  6 , C Bierman  4 , T J M Ruers  1   2 , C U Blank  3 , A C J van Akkooi  1
Affiliations
Randomized Controlled Trial

Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma

B Schermers et al. Br J Surg. 2019 Apr.

Abstract

This pilot study explored the value of localized index node removal after neoadjuvant immunotherapy in patients with stage III melanoma, for use as a response indicator to guide the extent of completion lymph node dissection. Promising technology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overview of the magnetic seed localization procedure a Proprietary magnetic seed on finger. b Correct positioning of the needle tip (red arrow) in lymph node (green arrow) before implantation. c Magnetic detector (Endomag Sentimag®) used during surgery to detect the seed. d Postoperative specimen X‐ray with magnetic seed (red arrow) in situ.
See this image and copyright information in PMC

References

    1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199–6206. - PMC - PubMed
    1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723. - PMC - PubMed
    1. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006–2017. - PMC - PubMed
    1. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al.; KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521–2532. - PubMed
    1. Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018; 24: 1655–1661. - PubMed

Publication types

MeSH terms